Paper41565210
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.
Xia H and 7 others. Eur Heart J Cardiovasc Pharmacother, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system. Papers, record 41565210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41565210
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immune Checkpoint Inhibitors | Major topic |
| United States Food and Drug Administration | Major topic |
| Heart Diseases | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Pharmacovigilance | |
| United States | |
| Adverse Drug Reaction Reporting Systems | |
| Cardiotoxicity | |
| Female | |
| Male | |
| Databases, Factual | |
| Risk Factors | |
| Risk Assessment | |
| Middle Aged | |
| Time Factors | |
| Aged | |
| Treatment Outcome | |
| Retrospective Studies | |
| Adult |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2023J011254 | Natural Science Foundation of Fujian Province | PubMed | ||
| 2022ZQNZD009 | Young and Middle-aged Scientific Research Major Project of Fujian Provincial Health Commission | PubMed | ||
| 2023Y9412 | Joint Funds for the Innovation of Science and Technology, Fujian province | PubMed | ||
| 202410392008 | Fujian Medical University Student Innovation and EntrepreneurshipTraining Project, China | PubMed | ||
| 2023L3020 | Special Research Funds for Local Science and Technology Development Guided by Central Government | PubMed | ||
| 82350126 | National Natural Science Foundation of China | PubMed | ||
| 2021QH1278 | Fujian Medical University | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 41849665 | Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions. | https://conductscience.org/library/papers/41849665 |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36600271 | Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36600271 | PubMed |
| 2 | 37326100 | New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). | Int J Oncol | 2023 | https://conductscience.org/library/papers/37326100 | PubMed |
| 3 | 35068882 | Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities. | Acta Cardiol Sin | 2022 | https://conductscience.org/library/papers/35068882 | PubMed |
| 4 | 36808819 | Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population-based self-controlled case series. | Cancer Med | 2023 | https://conductscience.org/library/papers/36808819 | PubMed |
| 5 | 32257944 | Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. | Front Oncol | 2020 | https://conductscience.org/library/papers/32257944 | PubMed |
| 6 | 33643048 | Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33643048 | PubMed |
| 7 | 28889792 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28889792 | PubMed |
| 8 | 26027431 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26027431 | PubMed |
| 9 | 40884033 | Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. | Eur Heart J | 2026 | https://conductscience.org/library/papers/40884033 | PubMed |
| 10 | 38375475 | Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. | Front Immunol | 2024 | https://conductscience.org/library/papers/38375475 | PubMed |
| 11 | 31636208 | Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/31636208 | PubMed |
| 12 | 36017568 | 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). | Eur Heart J | 2022 | https://conductscience.org/library/papers/36017568 | PubMed |
| 13 | 33937956 | Cardiotoxicity of Immune Checkpoint Inhibitors. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/33937956 | PubMed |
| 14 | 37651086 | Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. | Drug Saf | 2023 | https://conductscience.org/library/papers/37651086 | PubMed |
| 15 | 33705549 | Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/33705549 | PubMed |
| 16 | 39333574 | Clinical characteristics and influencing factors of anti-PD-1/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases. | Sci Rep | 2024 | https://conductscience.org/library/papers/39333574 | PubMed |
| 17 | 40569849 | Immune checkpoint inhibitor-associated myocarditis: a novel risk score. | Eur Heart J | 2026 | https://conductscience.org/library/papers/40569849 | PubMed |
| 18 | 38382875 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. | Ann Oncol | 2024 | https://conductscience.org/library/papers/38382875 | PubMed |
| 19 | 35277208 | Cardiotoxicity risk factors with immune checkpoint inhibitors. | Cardiooncology | 2022 | https://conductscience.org/library/papers/35277208 | PubMed |
| 20 | 27141885 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/27141885 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42718552 | Peripheral blood cells and immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study with pharmacovigilance and single-cell analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42718552 | PubMed |
| 42591858 | Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42591858 | PubMed |
| 41849665 | Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions. | Eur Heart J Cardiovasc Pharmacother | 2026 | https://conductscience.org/library/papers/41849665 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41565210
GET https://conductscience.org/api/papers/v1/41565210/references?page=2